(Q50577568)

15 March 2018

http://europepmc.org/abstract/MED/28653862

title

Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile (English)

1 reference

15 March 2018

http://europepmc.org/abstract/MED/28653862

author

Luisa M Villar

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28653862%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Susana Sainz de la Maza

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28653862%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

José Lifante

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28653862%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Silvia Medina

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28653862%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Noelia Villarrubia

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28653862%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Lucienne Costa-Frossard

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28653862%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Ernesto Roldán

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28653862%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Carmen Picón

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28653862%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

José C Álvarez-Cermeño

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28653862%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

1 June 2017

1 reference

15 March 2018

http://europepmc.org/abstract/MED/28653862

published in

Multiple Sclerosis Journal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28653862%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28653862%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28653862%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

1317-1327

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28653862%20AND%20SRC:MED&resulttype=core&format=json

Multiple sclerosis-a quiet revolution

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Disease-modifying treatments for multiple sclerosis - a review of approved medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Increased CD8+ central memory T cells in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

CD56bright natural killer (NK) cells: an important NK cell subset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517717088

21 January 2018

Identifiers

DOI

10.1177/1352458517717088

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28653862%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference